Patents by Inventor Philipp Hadwiger

Philipp Hadwiger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110251263
    Abstract: The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.
    Type: Application
    Filed: June 22, 2011
    Publication date: October 13, 2011
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Heiko Van Der Kuip
  • Patent number: 8034793
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: October 11, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • Publication number: 20110245320
    Abstract: This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.
    Type: Application
    Filed: March 2, 2011
    Publication date: October 6, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Hans-Peter VORNLOCHER, Ingo ROEHL, Philipp HADWIGER, Tracy Stage ZIMMERMANN, Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Akin AKINC
  • Publication number: 20110224282
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Application
    Filed: March 8, 2011
    Publication date: September 15, 2011
    Inventors: Antonin De Fougerolles, Maria Frank-Kamenetsky, Muthiah Manoharan, Kallanthottathil G. Rajeev, Philipp Hadwiger
  • Publication number: 20110207799
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 25, 2011
    Applicant: ROCHE MADISON INC.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Patent number: 7994307
    Abstract: The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: August 9, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Heiko Van Der Kuip
  • Publication number: 20110124711
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene in a cell.
    Type: Application
    Filed: January 28, 2011
    Publication date: May 26, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Dinah Sah, Maria Frank-Kamenetsky, Anke Geick, Philipp Hadwiger, Ingo Roehl, Pamela Tan, Hans-Peter Vornlocher
  • Patent number: 7947659
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: May 24, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Maria Frank-Kamenetsky, Muthiah Manoharan, Kallanthottathil G. Rajeev, Philipp Hadwiger
  • Publication number: 20110111493
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3?-end and a blunt 5?-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
    Type: Application
    Filed: September 29, 2010
    Publication date: May 12, 2011
    Inventors: Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
  • Patent number: 7928217
    Abstract: This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: April 19, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, Ingo Roehl, Philipp Hadwiger, Tracy Stage Zimmermann, Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc
  • Patent number: 7919473
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: April 5, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin De Fougerolles, Maria Frank-Kamenetsky, Muthiah Manoharan, Kallanthottathil G. Rajeev, Philipp Hadwiger
  • Patent number: 7906484
    Abstract: The present invention relates to compositions and methods for the delivery of an anionic substance using complexes, comprising the anionic substance and a peptide. These complexes are useful for delivering said anionic substance into a cell, particularly in therapeutic applications.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: March 15, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Philipp Hadwiger, Anke Geick
  • Patent number: 7902168
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: March 8, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Maria Frank-Kamenetsky, Anke Geick, Philipp Hadwiger, Ingo Roehl, Pamela Tan, Hans-Peter Vornlocher
  • Publication number: 20100298405
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: April 2, 2009
    Publication date: November 25, 2010
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Publication number: 20100292305
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1?, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Application
    Filed: April 2, 2010
    Publication date: November 18, 2010
    Inventors: Akin Akinc, Antonin de Fougerolles, Hans-Peter Vornlocher, Philipp Hadwiger, Birgit Bramlage
  • Patent number: 7829693
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3?-end and a blunt 5?-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: November 9, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
  • Publication number: 20100280102
    Abstract: The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs.
    Type: Application
    Filed: June 16, 2010
    Publication date: November 4, 2010
    Applicant: Alnylam Pharmaceuticals
    Inventors: Claudia Woppmann, Hans-Peter Vornlocher, Philipp Hadwiger, Matthias John, Stefan Limmer
  • Publication number: 20100256218
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Application
    Filed: February 4, 2010
    Publication date: October 7, 2010
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • Publication number: 20100234446
    Abstract: The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.
    Type: Application
    Filed: July 27, 2009
    Publication date: September 16, 2010
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Heiko Van Der Kuip
  • Patent number: 7786290
    Abstract: The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: August 31, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Claudia Woppmann, Hans-Peter Vornlocher, Philipp Hadwiger, Matthias John, Stefan Limmer